Answers are grounded in this paper and cite their sources.
Review discusses HER2-low tumors, their biological significance, and therapeutic implications for breast cancer management.
Breast cancer is classified, based on human epidermal growth factor receptor 2 (HER2) status, as HER2‑positive or HER2‑negative, guiding eligibility for HER2‑targeted therapies. A HER2‑low tumor is a type of breast cancer, which is defined by immunohistochemistry scores of 1+ or 2+ with negative in situ hybridization. Technological advances in HER2 testing, along with improved diagnostic precision, have increased the recognition of the HER2‑low subgroup. HER2‑low tumors may represent a distinct biological and clinical entity. Molecular profiling further demonstrates the unique transcriptomic and mutational signatures of HER2‑low tumors, particularly within hormone receptor‑positive contexts. In addition, clinical trials such as DESTINY‑Breast04, demonstrate notable efficacies for novel antibody‑drug conjugates, such as trastuzumab‑deruxtecan, in patients with HER2‑low tumors. This challenges the conventional HER2 stratification and suggests guideline revisions in order to acknowledge the HER2‑low status. The present review synthesized knowledge regarding HER2 biology, pathology and molecular features, and highlighted the clinical relevance and therapeutic implications of redefining HER2 status to include the HER2‑low subgroup. Recognizing HER2‑low as a discrete classification may refine patient stratification, optimize therapeutic selection and improve clinical outcomes in breast cancer management.
No takes yet. Share an insight, caveat, or question.
Georgiou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: